Latest Breaking News On - Stefan riley - Page 9 : comparemela.com

Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation Data from ongoing phase 1 COVID-19 study show that MP0420 (ensovibep) is well tolerated in first dose cohort Unique immunomodulation platforms advanced to readiness for candidate generation using CD-3 T cell engagers and pMHC binders Virology portfolio launched with focus on major global viral threats where unique DARPin® therapeutic profile could make major impact ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / December 17, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced multiple advances across clinical and preclinical programs, as well as an expansion of it

United statesSeth lewisLutz hegemannThomas schneckenburgerPatrick amstutzStefan rileyMario sznolAmerican association for cancer researchGlobal healthCancer immunology at yale centerCompany on twitter at molecularprtnrsMolecular partnersVirtual rd dayChief operating officerMedical oncologyCancer immunology